nouvelles
les langues
Live Cam
contact
empreinte
Ulm
Français
fr
English
en
Deutsch
de
nouvelles
les langues
Live Cam
contact
empreinte
Français
fr
English
en
Deutsch
de
EKM WS18 Introduction à la médecine clinique
GTE Développement historique de la médecine
Medizin
Button
Robert Koch Institut
Rote Liste
Pub Med
Dolosys
cardiologie
JUL
21
Regulatory T cells protect the heart in hypertrophic cardiomyopathy
By:
Irene Fernández-Ruiz
on
JUL
21
Nature Reviews Cardiology, Published online: 21 July 2025; doi:10.1038/s41569-025-01196-1Immune cells contribute to pathological remodelling in hypertrophic cardiomyopathy but regulatory T cells in particular can attenuate cardiac fibrosis and systolic dysfunction through their immunosuppressive properties, according to a new study.
En savoir plus >>
JUL
21
European guidelines for hypertension in 2024: a comparison of key recommendations for clinical practice
By:
Lucas Lauder
on
JUL
21
Nature Reviews Cardiology, Published online: 21 July 2025; doi:10.1038/s41569-025-01187-2In this Expert Recommendation, Lauder and colleagues compare the latest European Society of Cardiology and European Society of Hypertension guidelines on hypertension, highlight the key consensus recommendations and compare differing approaches to definitions, classification, diagnosis and treatment, with the aim to help health-care professionals in their decision-making to improve the management of hypertension.
En savoir plus >>
JUL
18
Metabolites matter for gut microbiota as a modifiable risk factor in cardiovascular diseases
By:
Seyed Soheil Saeedi Saravi
on
JUL
18
Nature Reviews Cardiology, Published online: 18 July 2025; doi:10.1038/s41569-025-01193-4Seyed Soheil Saeedi Saravi discusses the seminal study that linked a gut microbial metabolite to atherosclerotic cardiovascular disease and opened the way to mechanistic studies assessing how the gut microbiota influences host cardiovascular health.
En savoir plus >>
JUL
18
Myocardial infarction, stroke and arterial stenosis: time to reassess a major misunderstanding
By:
Luca Saba
on
JUL
18
Nature Reviews Cardiology, Published online: 18 July 2025; doi:10.1038/s41569-025-01186-3In this Perspective article, Saba and Libby review the latest evidence highlighting the lack of a correlation between stenosis severity and the risk of atherosclerosis-induced thrombotic complications and question the overreliance on stenosis grading for therapeutic decision-making.
En savoir plus >>
JUL
17
Lipoprotein(a) in coronary artery disease
By:
Jae Hyun Byun
on
JUL
17
Nature Reviews Cardiology, Published online: 17 July 2025; doi:10.1038/s41569-025-01194-3Jae Hyun Byun and Stella S. Daskalopoulou describe the study that identified lipoprotein(a) as a genetically determined contributor to coronary artery disease.
En savoir plus >>
JUL
16
Access to digital health technologies: personalized framework and global perspectives
By:
Sanjiv M. Narayan
on
JUL
16
Nature Reviews Cardiology, Published online: 16 July 2025; doi:10.1038/s41569-025-01184-5In this Review, Narayan and colleagues discuss global disparities in access to digital health technologies, with a focus on cardiovascular medicine. The authors summarize the factors that affect access at various levels of society and present solutions that target each of these levels, culminating in a personalized framework to improve access to digital health technologies.
En savoir plus >>
JUL
04
Publisher Correction: Wearable blood pressure sensors for cardiovascular monitoring and machine learning algorithms for blood pressure estimation
By:
Seongwook Min
on
JUL
04
Nature Reviews Cardiology, Published online: 04 July 2025; doi:10.1038/s41569-025-01189-0Publisher Correction: Wearable blood pressure sensors for cardiovascular monitoring and machine learning algorithms for blood pressure estimation
En savoir plus >>
JUN
27
Tailored therapeutics for cardiomyopathies
By:
Athanasios Bakalakos
on
JUN
27
Nature Reviews Cardiology, Published online: 27 June 2025; doi:10.1038/s41569-025-01183-6Treatment of cardiomyopathies has historically focused on symptom management. In this Review, Elliott and colleagues discuss how elucidation of the complex cellular and molecular pathways has led to the development of novel therapeutic agents that modify or mitigate the effects of causative genetic variants, enabling tailored treatment for cardiomyopathies.
En savoir plus >>
Weitere Beiträge
Oncologie clinique
JUL
22
PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER
+
HER2
−
breast cancer harbouring acquired
ESR1
mutations
By:
Patrick Neven
on
JUL
22
Nature Reviews Clinical Oncology, Published online: 22 July 2025; doi:10.1038/s41571-025-01062-6Next-generation, oral selective oestrogen receptor degraders (SERDs) have been shown to improve outcomes in patients with advanced-stage oestrogen receptor (ER)-positive, HER2-negative breast cancer, particularly those with acquired ESR1 mutations. Now, the proteolysis-targeting chimera (PROTAC) SERD vepdegestrant, which induces ER degradation directly rather than indirectly, has also demonstrated efficacy in this setting, raising questions over the optimal choice and sequencing of treatments.
En savoir plus >>
JUL
22
EMT and cancer: what clinicians should know
By:
Erik W. Thompson
on
JUL
22
Nature Reviews Clinical Oncology, Published online: 22 July 2025; doi:10.1038/s41571-025-01058-2Despite several decades of research that has revealed roles in the development and progression of many solid tumours, clinical translation of research targeting epithelial–mesenchymal transition (EMT) has thus far been limited. In this Review, the authors provide a summary of the role of EMT in cancer development and progression in the context of this lack of clinical translation, summarize the current status of direct or indirect EMT-modulating agents in clinical development, and highlight the major barriers to the development of EMT-related clinical interventions.
En savoir plus >>
JUL
18
Evolving roles of MET as a therapeutic target in NSCLC and beyond
By:
Jii Bum Lee
on
JUL
18
Nature Reviews Clinical Oncology, Published online: 18 July 2025; doi:10.1038/s41571-025-01051-9MET mutations, amplifications and fusions and MET overexpression are promising therapeutic targets across various cancers. In this Review, the authors summarize the prevalence, molecular diagnosis and prognostic implications of these alterations and discuss the clinical efficacy and toxicity profiles of diverse MET-targeted therapies, including tyrosine-kinase inhibitors, monoclonal or bispecific antibodies and antibody–drug conjugates.
En savoir plus >>
JUL
14
The microbiota in radiotherapy-induced cancer immunosurveillance
By:
Jianzhou Chen
on
JUL
14
Nature Reviews Clinical Oncology, Published online: 14 July 2025; doi:10.1038/s41571-025-01052-8Radiotherapy has an established role in the treatment of many patients with cancer, with evidence suggesting that this modality can also have immunostimulatory effects in certain scenarios. More recently, evidence has emerged supporting a role of the microbiome in influencing the incidence and severity of toxicities in patients receiving radiotherapy as well as in mediating possible synergy with other therapeutic interventions, including immunotherapy. In this Review, the authors explore the clinical potential of these emerging relationships.
En savoir plus >>
JUL
10
Therapeutic targeting of mismatch repair-deficient cancers
By:
Paul Johannet
on
JUL
10
Nature Reviews Clinical Oncology, Published online: 10 July 2025; doi:10.1038/s41571-025-01054-6This comprehensive Review describes the biological function of the mismatch repair (MMR) machinery, the genomic sequelae of defects in this machinery and the roles of hereditary or sporadic MMR deficiency in cancer predisposition and/or tumour development. The authors also discuss the clinical implications of MMR deficiency with a specific focus on diagnostic approaches, therapeutic strategies and mechanisms of resistance to immune-checkpoint inhibitors.
En savoir plus >>
JUL
07
EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma
By:
Meletios A. Dimopoulos
on
JUL
07
Nature Reviews Clinical Oncology, Published online: 07 July 2025; doi:10.1038/s41571-025-01041-xIn these Evidence-Based Guidelines, a multidisciplinary panel of experts from the European Hematology Association and the European Myeloma Network provide key treatment recommendations for patients with smouldering multiple myeloma, and newly diagnosed or relapsed and/or refractory multiple myeloma, addressing the use of established drugs and novel immunotherapies as well as the management of disease-specific and treatment-related complications and adverse events.
En savoir plus >>
JUL
03
Perioperative pembrolizumab demonstrates clinical benefit in locally advanced HNSCC
By:
David Killock
on
JUL
03
Nature Reviews Clinical Oncology, Published online: 03 July 2025; doi:10.1038/s41571-025-01057-3Perioperative pembrolizumab demonstrates clinical benefit in locally advanced HNSCC
En savoir plus >>
JUL
01
A new first-line option for advanced-stage anal squamous cell carcinoma
By:
Diana Romero
on
JUL
01
Nature Reviews Clinical Oncology, Published online: 01 July 2025; doi:10.1038/s41571-025-01056-4A new first-line option for advanced-stage anal squamous cell carcinoma
En savoir plus >>
Weitere Beiträge
endocrinologie
JUL
21
Combined amylin analogue and GLP1 receptor agonist therapies are highly promising for weight loss
By:
Olivia Tysoe
on
JUL
21
Nature Reviews Endocrinology, Published online: 21 July 2025; doi:10.1038/s41574-025-01156-2Combined amylin analogue and GLP1 receptor agonist therapies are highly promising for weight loss
En savoir plus >>
JUL
17
Language evolves — so can you
By:
Sarah C. Westen
on
JUL
17
Nature Reviews Endocrinology, Published online: 17 July 2025; doi:10.1038/s41574-025-01155-3As healthcare professionals, scientists and educators, our intent is to empower people affected by diabetes mellitus; however, if our language is stigmatizing, our impact might be disempowerment. If we do not choose our words with care, we risk undermining the very autonomy we seek to promote.
En savoir plus >>
JUL
16
The role of GLP1 receptor agonists in adult-onset type 1 diabetes mellitus
By:
Djordje S. Popovic
on
JUL
16
Nature Reviews Endocrinology, Published online: 16 July 2025; doi:10.1038/s41574-025-01154-4Adult-onset type 1 diabetes mellitus differs from the early onset form in terms of residual endogenous insulin secretion, comorbidities and baseline cardiorenal risk. Adjunct therapy with glucagon-like peptide 1 receptor agonists could offer benefits in this population of patients by preserving β-cell mass and function while also contributing to cardiorenal risk mitigation.
En savoir plus >>
JUL
14
Can obesity pharmacotherapy be used to manage male infertility?
By:
Amy E. Morrison
on
JUL
14
Nature Reviews Endocrinology, Published online: 14 July 2025; doi:10.1038/s41574-025-01151-7Obesity-related subfertility is an increasingly recognized concern. Pharmacotherapies (particularly glucagon-like peptide 1 receptor agonists and combination therapies), alongside lifestyle intervention, enable meaningful and sustainable weight loss in people with and without type 2 diabetes mellitus. Weight loss can benefit sperm parameters, but the optimal amount and rate of weight loss requires further study.
En savoir plus >>
JUL
14
Bile acids in the crosshairs for hypoglycaemia after gastric bypass
By:
Marzieh Salehi
on
JUL
14
Nature Reviews Endocrinology, Published online: 14 July 2025; doi:10.1038/s41574-025-01153-5Bile acids are increasingly recognized for their broad metabolic effects, including the regulation of glucose homeostasis. In a recent study published in Nature Metabolism, researchers provide compelling evidence that alteration in bile acid flux — namely, in intestinal absorption and faecal secretion — can directly influence prandial glucose metabolism.
En savoir plus >>
JUL
14
The role of ultra-processed food in obesity
By:
Filippa Juul
on
JUL
14
Nature Reviews Endocrinology, Published online: 14 July 2025; doi:10.1038/s41574-025-01143-7Consumption of ultra-processed foods (UPF) is increasingly linked to the development of obesity, on both an individual and a global scale. This Review assesses the role of UPF in obesity, examining the epidemiological evidence, biological mechanisms and implications for policymakers.
En savoir plus >>
JUL
08
Glycogen metabolism: not just a one-trick pony
By:
Dipsikha Biswas
on
JUL
08
Nature Reviews Endocrinology, Published online: 08 July 2025; doi:10.1038/s41574-025-01152-6Glycogen metabolism: not just a one-trick pony
En savoir plus >>
JUL
07
mRNA-based enzyme replacement for propionic acidaemia
By:
Chuang Liu
on
JUL
07
Nature Reviews Endocrinology, Published online: 07 July 2025; doi:10.1038/s41574-025-01150-8mRNA-based enzyme replacement for propionic acidaemia
En savoir plus >>
Weitere Beiträge
hépatologie
JUL
21
Rethinking gastric cancer prevention through an immigrant health lens
By:
Chul S. Hyun
on
JUL
21
Nature Reviews Gastroenterology & Hepatology, Published online: 21 July 2025; doi:10.1038/s41575-025-01098-0Gastric cancer is often overlooked in the United States, yet East Asian and other immigrant communities face a markedly increased burden. A community-based, migration-informed approach is needed to strengthen prevention and reduce disparities.
En savoir plus >>
JUL
21
Black–White disparities across the colorectal cancer care continuum in the USA
By:
Folasade P. May
on
JUL
21
Nature Reviews Gastroenterology & Hepatology, Published online: 21 July 2025; doi:10.1038/s41575-025-01087-3In the USA, colorectal cancer (CRC) is a leading cause of death and a public health challenge due to persisting disparities between Black and White individuals. This Review examines Black–White disparities in CRC outcomes, bringing health-care and systemic inequities into focus.
En savoir plus >>
JUL
18
The global burden of inflammatory bowel disease: from 2025 to 2045
By:
Gilaad G. Kaplan
on
JUL
18
Nature Reviews Gastroenterology & Hepatology, Published online: 18 July 2025; doi:10.1038/s41575-025-01097-1The global burden of inflammatory bowel disease (IBD) is shifting as countries transition through four epidemiologic stages. This Perspective explores the global evolution of IBD over the next 20 years and proposes strategies for prevention and health-care innovation.
En savoir plus >>
JUL
07
Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma
By:
Harry Cheuk-Hay Lau
on
JUL
07
Nature Reviews Gastroenterology & Hepatology, Published online: 07 July 2025; doi:10.1038/s41575-025-01089-1In this Review, Yu and colleagues describe the role of the gut microbiome and the gut–liver axis in metabolic dysfunction-associated steatotic liver disease (MASLD) and MASLD-related hepatocellular carcinoma (HCC). They discuss clinical implications for the diagnosis and treatment of MASLD and MASLD-related HCC.
En savoir plus >>
JUL
02
Intestinal pH: a major driver of human gut microbiota composition and metabolism
By:
Julius E. Brinck
on
JUL
02
Nature Reviews Gastroenterology & Hepatology, Published online: 02 July 2025; doi:10.1038/s41575-025-01092-6In humans, pH varies across the gastrointestinal tract. This Review provides an overview of gastrointestinal pH and its role in shaping the gut microbiota, highlighting major physiological and dietary factors that influence gastrointestinal pH and how in turn pH affects microbiota composition and metabolism in health and, potentially, disease.
En savoir plus >>
JUN
27
Reply to ‘Pregnancy and liver health: delivering new collaborations to advance the MASLD and MASH field’
By:
Alina M. Allen
on
JUN
27
Nature Reviews Gastroenterology & Hepatology, Published online: 27 June 2025; doi:10.1038/s41575-025-01095-3Reply to ‘Pregnancy and liver health: delivering new collaborations to advance the MASLD and MASH field’
En savoir plus >>
JUN
27
Lessons from incretin-based therapy in MASH and obesity
By:
Herbert Tilg
on
JUN
27
Nature Reviews Gastroenterology & Hepatology, Published online: 27 June 2025; doi:10.1038/s41575-025-01096-2Glucagon-like peptide 1 receptor agonists are effective pharmacotherapies for the treatment of obesity and related disorders. In metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis, semaglutide improved liver histology over 72 weeks. In another new study, tirzepatide was superior to semaglutide in reducing body weight in individuals with obesity.
En savoir plus >>
JUN
27
Pregnancy and liver health: delivering new collaborations to advance the MASLD and MASH field
By:
Luiza Borges Manna
on
JUN
27
Nature Reviews Gastroenterology & Hepatology, Published online: 27 June 2025; doi:10.1038/s41575-025-01094-4Pregnancy and liver health: delivering new collaborations to advance the MASLD and MASH field
En savoir plus >>
Weitere Beiträge
néphrologie
neurologie
rhumatologie
JUL
21
Addressing the challenge of global delays in diagnosis and treatment of systemic lupus erythematosus
By:
Guillermo J. Pons-Estel
on
JUL
21
Nature Reviews Rheumatology, Published online: 21 July 2025; doi:10.1038/s41584-025-01277-yDelays in the diagnosis of systemic lupus erythematosus negatively affect the treatment, quality of life and outcomes of affected individuals. In this Perspective, the authors provide an overview of the contributing factors and consequences of diagnostic delay in systemic lupus erythematosus and discuss how this urgent issue should be addressed.
En savoir plus >>
JUL
10
Guided management of familial Mediterranean fever
By:
Hatem El-Shanti
on
JUL
10
Nature Reviews Rheumatology, Published online: 10 July 2025; doi:10.1038/s41584-025-01281-2Familial Mediterranean fever (FMF) is a monogenic autoinflammatory disorder with high prevalence in Mediterranean populations. Considerable advances in the management of FMF have been made in the past decade, with respect to the use of biologic drugs and understanding colchicine resistance. The 2024 updated FMF management recommendations are timely and reflect these advances.
En savoir plus >>
JUL
10
Insights into chondrocyte populations in cartilaginous tissues at the single-cell level
By:
Csaba Matta
on
JUL
10
Nature Reviews Rheumatology, Published online: 10 July 2025; doi:10.1038/s41584-025-01275-0This Review provides an update on chondrocyte heterogeneity in cartilaginous tissues in health, disease and senescence focusing on insights gained from single-cell analyses. The authors highlight how single-cell multi-omics techniques could reveal new biomarkers and therapeutic targets for conditions such as osteoarthritis and intervertebral disc degeneration.
En savoir plus >>
JUL
08
Synovial fibroblast-mediated neovascularization in RA
By:
Holly Webster
on
JUL
08
Nature Reviews Rheumatology, Published online: 08 July 2025; doi:10.1038/s41584-025-01283-0A study provides insights into the factors that regulate synovial fibroblast interactions with endothelial cells in RA and subsequent pathogenic neovascularization.
En savoir plus >>
JUL
08
Tissue-resident memory CD8
+
T cells on the skin–joint route
By:
Maria Papatriantafyllou
on
JUL
08
Nature Reviews Rheumatology, Published online: 08 July 2025; doi:10.1038/s41584-025-01284-zSkin- and joint-resident CD8+ T cells that share clonality also share phenotypic similarities in psoriatic arthritis.
En savoir plus >>
JUL
08
Nerandomilast slows progression of pulmonary fibrosis
By:
Maria Papatriantafyllou
on
JUL
08
Nature Reviews Rheumatology, Published online: 08 July 2025; doi:10.1038/s41584-025-01285-yThe anti-fibrotic and anti-inflammatory agent nerandomilast has shown promise for the treatment of both idiopathic and progressive pulmonary fibrosis in phase III trials.
En savoir plus >>
JUL
07
Synovial fluid as a complex molecular pool contributing to knee osteoarthritis
By:
Hayley Peters
on
JUL
07
Nature Reviews Rheumatology, Published online: 07 July 2025; doi:10.1038/s41584-025-01271-4The synovial fluid lubricates joints while also collecting molecular mediators from surrounding tissues. This Review highlights how molecular analyses of the synovial fluid might provide information on the progression of knee osteoarthritis and treatment efficacy, and identify potential therapeutic strategies targeting synovial fluid mediators in knee osteoarthritis.
En savoir plus >>
JUL
07
Platelets as drivers of immunothrombosis in rheumatic diseases
By:
Norma Maugeri
on
JUL
07
Nature Reviews Rheumatology, Published online: 07 July 2025; doi:10.1038/s41584-025-01276-zThis Review provides an overview of how platelets promote immunothrombosis in rheumatic disease. The authors discuss the different ways in which platelets and immunothrombosis can be targeted for therapeutic intervention.
En savoir plus >>
Weitere Beiträge
urologie
Partager
Tweet
Partager
Courrier
La version française de ce site est principalement traduite automatiquement par "google translate". En cas de difficultés linguistiques, n'hésitez pas à me contacter.
Share by: